Trial Profile
A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Iclepertin (Primary)
- Indications Schizophrenia
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183965).
- 24 May 2021 According Boehringer Ingelheim to a media release, US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).
- 15 Sep 2020 Results of psychometric evaluation of a patient-reported outcome measure presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology